Moderna receives U.S. FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2
Moderna Inc. announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2… read more.